Ipca Laboratories receives VAI classification from the USFDA

Ipca Laboratories stated that the US Food and Drug Administration (USFDA) has given its Piparia (Silvassa) production facility a voluntary action indicated (VAI) classification.

"This classification means that the facility was found to be adhering to a minimally acceptable state of compliance with regards to current good manufacturing practice," the company said.

According to USFDA, VAI means objectionable conditions or practices were found but the agency (here, USFDA) is not prepared to take or recommend any administrative or regulatory action. This is considered to be the second-best classification after ‘no action indicated’ and before ‘official action indicated.’

Ipca Laboratories is in the pharmaceutical production sector. The company specializes in the manufacture of generic APIs and formulations, primarily for the therapeutic market.

Source: Media Reports